Paving the way to make cell therapy accessible to the world

iPSC-based platforms that accelerate the development and manufacture of your cell therapies

START A CONVERSATION

Paving the way to make cell therapy accessible to the world

iPSC-based platforms that accelerate the development and manufacture of your cell therapies

Leading the Future of Cell Therapy Manufacturing

At Cellistic, we believe the real potential of cell therapy is allogeneic and iPSC-based – and it’s ready to be unlocked. We’ve founded our company to accelerate the development and manufacture of your cell therapies in a more reliable, affordable, and faster way, using our exclusive Pulse + Echo Platforms. 

This family of established manufacturing processes for cell line development and cell therapy manufacturing can take your innovation from idea to edited and banked iPSCs, and then from iPSCs to drug product – all while keeping it in the expert hands of a single, experienced development team.

Leading the Future of Cell Therapy Manufacturing

At Cellistic, we believe the real potential of cell therapy is allogeneic and iPSC-based – and it’s ready to be unlocked. We’ve founded our company to accelerate the development and manufacture of your cell therapies in a more reliable, affordable, and faster way, using our exclusive Pulse + Echo Platforms. 

This family of established manufacturing processes for cell line development and cell therapy manufacturing can take your innovation from idea to edited and banked iPSCs, and then from iPSCs to drug product – all while keeping it in the expert hands of a single, experienced development team.

_PH-Pulse-Mark

Cell line development
From idea to edited iPSCs

Our Pulse Platform for cell line development provides everything you need – the tools, the systems, the space, and the thinking – to drive toward your perfect cell while dramatically reducing your timelines.

_PH_ADV-Purple

Streamlined idea-to-edited-iPSC development: We offer precise and proven reprogramming, gene editing, and cell banking technologies for accelerated development.

Unique, purpose-built capacity: We’ve invested heavily in automating and streamlining workflows, and enhancing data management for iPSCs.

Dedicated quality systems: Our integrated process controls and robust analytical testing strategies help ensure the highest quality GMP starting materials. 

_PH-Echo-Mark

Cell manufacturing
From banked iPSCs to drug product

Our Echo Platform for cell therapy manufacturing is built-to-scale to be highly efficient from the ground up, shortening your final mile to a final product.

_PH_ADV-Pink

Bespoke, flexible manufacturing capacity: Our facilities are designed for a single purpose – iPSC-based allogeneic immunotherapy.

Scaled NK production: Having already mastered critical manufacturing processes, we can produce multi-liter, feeder-free defined NK cells at at least 2 billion cells per liter.

T-cell generation from iPSCs: We’ve done it – repeatedly. We’ve met the high demands required for phenotypic purity, reprogramming efficiency, heterogeneity, etc.

Capitalize on our mastery of human biology and iPSCs

 

Talking about what’s possible is one thing. Proving it is quite another. That’s why we’re leveraging the know-how and experience of more than 120 professionals to demonstrate where we can set new benchmarks in cell therapy manufacturing – by achieving, for example, gene editing efficiencies in the high 90 percent range (with four or five edits at a time).

_PH_BTN-20
iPS cell types successfully differentiated and scaled
_PH_BTN-50
Therapies in development that leverage our science
_PH_BTN-300
Customers who’ve relied on our expertise to advance iPSC-based projects
_PH_BTN-25K
Square feet of iPSC development and manufacturing space

Capitalize on our mastery of human biology and iPSCs

 

Talking about what’s possible is one thing. Proving it is quite another. That’s why we’re leveraging the know-how and experience of more than 120 professionals to demonstrate where we can set new benchmarks in cell therapy manufacturing – by achieving, for example, gene editing efficiencies in the high 90 percent range (with four or five edits at a time).

_PH_BTN-20

iPS cell types successfully differentiated and scaled

_PH_BTN-300

Customers who’ve relied on our expertise to advance iPSC-based projects

_PH_BTN-50

Therapies in development that leverage our science

_PH_BTN-25K

Square feet of iPSC development and manufacturing space

Coming first quarter 2024

 

In Mont-Saint-Guibert, Belgium, we’ll soon open the world’s first facility exclusively dedicated to iPSC-based allogeneic cell therapy manufacturing.

Connect with us to schedule your personal tour.

Cellistic Facility Drawing

Meet Our Team

Gustavo Mahler, PhD
Gustavo Mahler, PhD
Chief Executive Officer

Gustavo Mahler is the Chief Executive Officer of Cellistic and its affiliate company, Ncardia. Gustavo brings Cellistic vast experience in stem cell technology, product development and general management.


Stefan Braam, PhD
Stefan Braam, PhD
Chief Technical Officer

Stefan Braam is the co-founder and Chief Technical Officer of Cellistic and its affiliate company, Ncardia. Stefan brings Cellistic over a decade of experience in stem cell technology, product development and general management.


Cellistic_Team Page_Jonas
Jonas Mortensen
Chief Commercial Officer

Jonas brings Cellistic vast experience in leading commercial teams to help cell therapy developers leverage Cellistic's new Pulse & Echo platforms to accelerate their cell line development and manufacturing at scale.


Cellistic_Team Page_Astrid
Astrid Norenberg, PhD
Head of Project Management

Astrid is Head of Project Management, leading the global project management function for Cellistic and its affiliate Ncardia. She is responsible to provide harmonized project management practices and a consistent customer experience across both organizations.


Cellistic_Team Page_Charles
Charles Jacques
Chief Financial Officer

Charles Jacques is the Chief Financial Officer, leading the global finance function for Cellistic and its affiliate Ncardia. In his new role, Charles leverages his experience in finance strategy for CDMO’s to help Cellistic accelerate its growth in the allogeneic immune cell therapy.


How can we help

 

As we’ve talked with cell therapy developers who are actively exploring iPSCs, those discussions ultimately tend to reflect three common concerns:

effect process
They’re seeking the most effective way to advance their therapy;
understanding partners
They’re looking for a partner that has more than just a basic understanding of iPSCs; and/or
maximize efficiency
They’re striving to ensure that they’re ideally positioned to maximize the efficiency of a future scale-up.
If those challenges sound familiar, Cellistic can help. Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing science and business drivers. We’re here to listen and, if you find us a good fit, to help you maximize the opportunity and value of your cell therapy.

How can we help

As we’ve talked with cell therapy developers who are actively exploring iPSCs, those discussions ultimately tend to reflect three common concerns:

Group-962

They’re seeking the most effective way to advance their therapy;

Group-964

They’re looking for a partner that has more than just a basic understanding of iPSCs; and/or

Group-971

They’re striving to ensure that they’re ideally positioned to maximize the efficiency of a future scale-up.

If those challenges sound familiar, Cellistic can help. Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing science and business drivers. We’re here to listen and, if you find us a good fit, to help you maximize the opportunity and value of your cell therapy.